AI Drug Discovery Predicative Oncology (POAI) Rises 70% on Successful Ovarian Cancer Study, Enters Biomarker Discovery Market

Today the PRISM NextGen Tech and AI Index leader Predicative Oncology (POAI) announced it will enter the $51.5M biomarker discovery market. This decision to expand their AI/ML driven drug discovery platform to pursue discovery of novel biomarkers that can be used to predict patient outcomes and drug response in oncology, comes on the heels of positive results obtained in the retrospective ovarian cancer study with UPMC Magee-Womens Hospital. These results were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. From this study, Predictive Oncology obtained and analyzed data that supports novel ovarian cancer biomarker discovery and development that will be further explored both independently and in partnership with biopharma companies.

“We believe the identification of novel cancer biomarkers represents the next significant opportunity for the application of our platform, which leverages the substantial value inherent in the diversified patient samples and data that we possess, as well as additional potential revenue streams for our company. Our technology has broad applicability, including the development of a clinical decision support tool to screen for clinical trial enrollment, and to inform subsequent drug discovery and development,” stated Raymond Vennare, Chief Executive Officer of Predictive Oncology.